Takeshi Tsutsumi

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Venues

Nature communications

Science advances

Cancers

This page only lists publications with an associated author ORCID identifier.

Publications

Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, Fu Gui, Takeshi Tsutsumi, Xiao Bai, Chenkui Miao, Chao Feng, Bin Gui, Zsofia Sztupinszki, Antoine Simoneau, Ning Xie, Ladan Fazli, Xuesen Dong, Haruhito Azuma, Atish D Choudhury, Kent W Mouw, Zoltan Szallasi, Lee Zou, Adam S Kibel, Li Jia
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nature communications 14 (1) (2023)
Chenkui Miao, Takuya Tsujino, Tomoaki Takai, Fu Gui, Takeshi Tsutsumi, Zsófia M Sztupinszki, Zengjun Wang, Haruhito Azuma, Zoltan Szallasi, Kent W Mouw, Lee Zou, Adam S Kibel, Li Jia
RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer. Science advances 8 (7) (2022)
Taizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, Takahiro Kimura, Kazuhiro Takahashi, Kazuki Nishimura, Keita Nakamori, Yuya Fujiwara, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Ryoichi Maenosono, Yuki Yoshikawa, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Naokazu Ibuki, Hajime Hirano, Hayahito Nomi, Kiyoshi Takahara, Teruo Inamoto, Shin Egawa, Haruhito Azuma
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers 13 (3) (2021)

Takeshi Tsutsumi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Takeshi Tsutsumi